CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - UNAUDITED - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
OPERATING CASH FLOW
Net earnings (loss)	$ 105	$ (139)
Adjustments to reconcile net earnings (loss) to operating cash flow:
Impairment	(63)	153
Depreciation and amortization	55	60
Change in fair value of warrant liabilities	(6)	0
(Earnings) loss from equity method investments, net of distributions	(14)	(8)
(Gain) loss on sales of assets incl. AMECO-North America	(15)	9
Loss on debt repurchases	0	20
Stock-based compensation	19	25
Deferred taxes	(10)	27
Net contributions to employee pension plans	0	(12)
Changes in assets and liabilities	(82)	(353)
Other	(4)	(2)
Operating cash flow	(15)	(220)
INVESTING CASH FLOW
Purchases of marketable securities	(313)	(73)
Proceeds from the sales and maturities of marketable securities	286	30
Capital expenditures	(38)	(55)
Proceeds from sales of assets	29	125
Investments in partnerships and joint ventures	(47)	(80)
Other	19	(12)
Investing cash flow	(64)	(65)
FINANCING CASH FLOW
Proceeds from NuScale de-SPAC transaction	341	0
Proceeds from sale of NuScale interest	107	0
Proceeds from issuance of CPS	0	582
Purchase and retirement of debt	(23)	(525)
Dividends paid on CPS	(29)	(9)
Other borrowings (debt repayments)	6	(7)
Distributions paid to NCI	(15)	(20)
Capital contributions by NCI	0	201
Other	(9)	(4)
Financing cash flow	378	218
Effect of exchange rate changes on cash	(72)	(6)
Increase (decrease) in cash and cash equivalents	227	(73)
Cash and cash equivalents at beginning of period	2,209	2,199
Cash and cash equivalents at end of period	2,436	2,126
SUPPLEMENTAL INFORMATION:
Cash paid for interest	43	81
Cash paid for income taxes (net of refunds)	$ 71	$ 59